Arbutus Biopharma (ABUS) Amortizatization of Intangibles (2019 - 2026)

Arbutus Biopharma (ABUS) has reported Amortizatization of Intangibles for 8 consecutive years, with $354000.0 the latest figure, recorded in Q1 2026.

• Quarterly Amortizatization of Intangibles fell 50.7% year-over-year to $354000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 39.85% YoY) and the FY2025 annual result came in at $2.3 million, down 25.07% from the prior year.
• Amortizatization of Intangibles retreated to $354000.0 in Q1 2026 per ABUS's latest filing, from $422000.0 in the prior quarter.
• Over the last five years, Amortizatization of Intangibles for ABUS reached as high as $983000.0 in Q3 2024 and fell as low as -$168000.0 in Q1 2022.
• A 5-year average of $475764.7 and a median of $541000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
• Annual changes were most pronounced in 2023 — Amortizatization of Intangibles jumped 743.37% — and 2025, when it plunged 54.28%.
• Year by year, Amortizatization of Intangibles stood at $224000.0 in 2022, then soared by 176.34% to $619000.0 in 2023, then jumped by 49.11% to $923000.0 in 2024, then tumbled by 54.28% to $422000.0 in 2025, then declined by 16.11% to $354000.0 in 2026.
• According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $354000.0, $422000.0, and $541000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.